Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|May 29, 1999
Neurologic protection by amifostineR S DiPaola, L Schuchter
Cellular Immunology|April 15, 1994
In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytesM Nakashima, T Watanabe, H Koprowski, et al.
Seminars in Oncology|May 29, 1999
Pharmacokinetics of amifostine: effects of dose and method of administrationL M Shaw, H S Bonner, L Schuchter, et al.
The Journal of Surgical Research|April 1, 1992
Anti-neoplastic effects of interleukin-4H P Redmond, L Schuchter, D Bartlett, et al.
Archives of Dermatology|January 6, 1999
Validation of a melanoma prognostic modelD J Margolis, A C Halpern, T Rebbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancerK D Miller, W Gradishar, L Schuchter, et al.
Medical Oncology (Northwood, London, England)|November 20, 1998
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferonR K Alpaugh, M von Mehren, I Palazzo, et al.
Annals of Internal Medicine|September 1, 1996
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion GroupL Schuchter, D J Schultz, M Synnestvedt, et al.
Annals of Plastic Surgery|May 16, 2001
Locally recurrent malignant melanoma characteristics and outcomes: a single-institution studyJ K Wildemore, L Schuchter, R Mick, et al.
Pageof 2